Table 3.

Multivariate analysis of RFI and OS for TNBC patients with chemotherapy and available TNBCtype-6 subtyping (n = 115)

Parameters	RFI (24 events)						OS (21 events)
	univariate analysis			multivariate analysis			univa			riate analysis			multivariate analysis
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Age at diagnosis ≤50 years 51–75 years >75 years	1.24 ref. 1.16	0.53–2.93 0.32–4.15	0.618 0.082				1.22 3.48	0.44–3.36 1.20–10.04	0.705 0.021
Tumor size at time of diagnosis <2 cm ≥2 cm	ref. 4.03	1.20–13.50	0.024	3.30	0.95–11.41	0.059	5.46	1.27–23.44	0.022	3.95	0.89–17.54	0.071
Nodal status at time of diagnosis Negative Positive	ref. 2.74	1.13–6.60	0.025	2.05	0.83–5.08	0.119	4.73	1.59–14.07	0.005	3.32	1.08–10.14	0.035
Tumor differentiation G1, G2 G3	ref 0.49	0.22–1.09	0.082				0.63	0.27–1.49	0.293
TNBCtype-6 Non-LAR LAR	ref. 1.89	0.70–5.07	0.204	1.87	0.69–5.05	0.211	2.79	1.08–7.20	0.033	2.74	1.06–7.10	0.037

CI, confidence interval; HR, hazard ratio; LAR, luminal androgen receptor; OS, overall survival; ref., reference group; RFI, recurrence-free interval; TNBC, triple-negative breast cancer.